ORQIS MEDICAL BEGINS EUROPEAN CLINICAL TRIAL FOR CRS SYSTEM.Orqis(TM) Medical, with European headquarters in Schaffhausen, Switzerland, is developing innovative devices for the treatment of Class III and IV Congestive Heart Failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. (CHF CHF In currencies, this is the abbreviation for the Swiss Franc. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ). The Cancion(TM) family of minimally invasive Cardiac Recovery Systems (CRS CRS Course CRS Certified Residential Specialist (real estate certification) CRS Central Reservation System CRS Can't Remember Stuff (polite form) CRS Cost Reduction Strategy CRS Consumer Relations Specialist ) has been used in clinical trials in Europe with encouraging results. The Orqis(TM) CRS uses leading-edge blood pumping technology, much of which has been developed in Switzerland and Germany. The CRS is ultimately intended for percutaneous insertion under local anesthesia Anesthesia, Local Definition Local or regional anesthesia involves the injection or application of an anesthetic drug to a specific area of the body, as opposed to the entire body and brain as occurs during general anesthesia. . The less invasive nature of this device is intended to broaden its potential application and may lower the cost of treatment for patients with chronic, acutely decompensated congestive heart failure. Orqis(TM) has received CE Mark certification and expects to launch the Cancion(TM) systems commercially in Europe in 2003. The company has also been granted five patents in the United States. The Orqis(TM) CRS is an external device, which supports the heart and circulatory system circulatory system, group of organs that transport blood and the substances it carries to and from all parts of the body. The circulatory system can be considered as composed of two parts: the systemic circulation, which serves the body as a whole except for the and allows the heart to rest. The benefits to early stage heart patients may include reduction of heart size and recovery of vital organ function. Professor Dr. Michael Bohm, University of Saarland, Germany, the principal investigator for Orqis(TM) suggested that, "Only new technologies like intelligent cardiac assist systems might be applicable in solving the great problems in the cure of patients with pumping failure refractory to medical therapy." Professor Dr. Andre Wasler, University of Graz The University of Graz (German, Karl-Franzens-Universität Graz), a university located in Graz, Austria, is the second-largest university in Austria. Karl-Franzens Universität, also referred to as the University of Graz, is the city's oldest university, founded in , Austria, who has used the Cancion(TM) system had found: "The Orqis(TM) CRS is an easy to implant, minimally invasive device. I was very impressed with the improvement of the hemodynamic he·mo·dy·nam·ics n. (used with a sing. verb) The study of the forces involved in the circulation of blood. he data of our first patient. The rapid improvement of kidney function was also remarkable. I am confident that this device will help a number of patients with heart failure." CHF is the leading cause of hospitalization and death for people over the age of 65 and affects more than 6.5 million people in Europe. Despite the availability of pharmacological agents and surgical treatment 50% of all patients die within five years of diagnosis. Orqis(TM) Medical International is located at Vordergasse 3, Schaffhausen CH-8201, Switzerland. For more information, call 949/786-8327 or visit http://www.orqis.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion